AngioDynamics pairs a bullish technical breakout and a three-quarter earnings beat streak — with another print in just 10 days — against a business quality score that sits below the engine's floor and options positioning that is unusually skewed toward puts, making this a momentum-and-catalyst trade rather than a quality-driven one.
Thesis pillars
- Quality Below Floor→Stable
- Bullish Breakout Setup↓Deteriorating
- Earnings Beat Streak→Stable
- +1 more pillar — see the Why tab for full reasoning
AngioDynamics, Inc. (ANGO) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $13.53: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
AngioDynamics designs, manufactures and sells medical devices for treating cardiovascular disease and cancer across two segments, Med Tech and Med Device, including the Auryon atherectomy system, AlphaVac thrombectomy devices and the NanoKnife ablation system. The company sells... Read more
Sell if holding. Engine safety override at $13.53: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 56 mid-range, Bollinger mid-band. Score 6.2/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 68d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About AngioDynamics, Inc.
About AngioDynamics, Inc.
AngioDynamics markets FDA-cleared devices across two segments, Med Tech and Med Device, anchored by the Auryon atherectomy system, the AlphaVac and AngioVac thrombectomy platforms, and the NanoKnife irreversible electroporation system, which received expanded FDA 510(k) clearance for prostate-tissue ablation in December 2024. The company manufactures primarily from Queensbury, New York, and reported international distributors represented approximately 74% of international revenue in fiscal 2025, a segment where sales fell 21% amid recent divestitures.
The company sells primarily through a direct sales force in the United States and a combination of direct sales and third-party distributors abroad, with sales and marketing focused on interventional radiologists, interventional cardiologists, vascular surgeons, urologists and interventional oncologists. Reimbursement flows through Medicare, Medicaid and private payers, and increasing purchasing power among group purchasing organizations and integrated health delivery networks has pushed AngioDynamics to compete more on price. Manufacturing is transitioning under a restructuring plan announced in January 2024 that shifts production from Queensbury, New York toward third-party manufacturers in Costa Rica, Latvia, Italy, Israel and China, including a supply agreement with Biomerics in Alajuela, Costa Rica. The company also depends on single and limited-source suppliers for several key raw materials and product components, a dependency it has flagged as a risk to uninterrupted manufacturing. Its primary competitors include Boston Scientific and Medtronic.
Show full overview
AngioDynamics faces a multidistrict product liability litigation in the U.S. District Court for the Southern District of California, consolidating numerous claims involving the company's port products, the outcome of which the 10-K states cannot be predicted. Separately, the company's manufacturing transition away from Queensbury, New York exposes it to execution risk: production is moving to third-party manufacturers in Costa Rica, Latvia, Italy, Israel and China under a restructuring plan first announced in January 2024 and modified in the second quarter of fiscal 2025, with completion targeted for the third quarter of fiscal 2026. A stumble in that multi-country handoff, layered on top of active litigation, would test the company's ability to sustain supply while defending its legacy device franchise.
See also: Healthcare · Medical Instruments & Supplies
From AngioDynamics, Inc.'s most recent 10-K filing, extracted July 19, 2026.
Recent developments
updated 2026-07-24Recent Developments — AngioDynamics, Inc.
Latest news
- NEWS HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19 — benzinga Jul 15, 2026 positive
- NEWS Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20 — benzinga Jul 15, 2026 positive
- NEWS Full Transcript: AngioDynamics Q4 2026 Earnings Call — benzinga Jul 14, 2026 positive
- NEWS Earnings Scheduled For July 14, 2026 — benzinga Jul 14, 2026 neutral
- NEWS AngioDynamics Sees FY2027 Adj EPS $(0.29)-$(0.24) vs $(0.16) Est; Sees Sales $336.000M-$341.000M vs $329.600M Est — benzinga Jul 14, 2026 negative
Generated 2026-07-25T09:22:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerinternational distributors74%10-K Item 1A: 'International distributors accounted for approximately 74% of international revenues for the fiscal year ended May 31, 2025.'
- HIGHSuppliersingle and limited source suppliers10-K Item 1A: 'We currently purchase significant amounts of several key products, raw materials and product components from single and limited source suppliers'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Unprofitable operations — net margin -11.5%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.53: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 56 mid-range, Bollinger mid-band. Prior stop was $12.58. Score 6.2/10, moderate confidence.
Take-profit target: $17.00 (+25.7% upside). Prior stop was $12.58. Stop-loss: $12.58.
Concentration risk — Customer: international distributors (74.0%); Concentration risk — Supplier: single and limited source suppliers; Quality below floor (3.9 < 4.0).
AngioDynamics, Inc. trades at a P/E of N/A (forward -298.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
10 analysts cover ANGO with a consensus score of 4.1/5. Average price target: $20.
What does AngioDynamics, Inc. do?AngioDynamics designs, manufactures and sells medical devices for treating cardiovascular disease and cancer across two...
AngioDynamics designs, manufactures and sells medical devices for treating cardiovascular disease and cancer across two segments, Med Tech and Med Device, including the Auryon atherectomy system, AlphaVac thrombectomy devices and the NanoKnife ablation system. The company sells largely through a direct U.S. sales force and a mix of direct sales and distributors abroad, manufacturing primarily out of Queensbury, New York while shifting some production to third-party manufacturers including Biomerics in Costa Rica.